drugset / Trial / NCT02915666

A Clinical Trial of Patients With Melanoma

NCT02915666

NaSingle-groupOpen-labelTreatment

Summary

This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.

Timeline

Start
2016-10
Primary completion
2017-07-17
Completion
2017-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabrafenib Small molecule 150 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Trametinib Small molecule 2 mg Oral

Indications